DavidSSiegelMDPhD

PubMed

• Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost.
  Ayrton Bangolo, Samir Oza, Ronit Reich-Slotky, Aimee Chappell, David S Siegel
  Current Stem Cell Research & Therapy. 2025-01-01
• Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myelo...
  Eli Zolotov, Maciej Kabat, Harsh Parmar, Palka Anand, Joshua Zenreich
  Leukemia & Lymphoma. 2024-12-01
• Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.
  Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous
  Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01

Journal Articles

• Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR  
  Ruben Niesvizky, David Siegel, Ralph Boccia, Blood
• Updated survival analyses after prolonged follow-up of the phase 2, multicenter CReST study of bortezomib in relapsed or refractory multiple myeloma  
  Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG,Niesvizky R, Alexanian R, Limentani SA, Alsina M, esseltine DL, Anderson KC, Br J Haematol, 1/1/2014
• Phase I Trial of Anti-CS1 Monoclonal Antibody elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma  
  Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar De, Singhal AK, Anderson KC, J Clin Oncol, 1/30/2012
• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma  
  Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewar..., Blood, 1/25/2012
• Liquid tumors in the elderly  
  Mato A, Feldman T, Richter J, Siegel DS, Goy A, Clin Geriatr Med, 1/1/2012
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study  
  SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, J Haessler, J Feather, A Hoering, P Moreau, X LeLeu, C Hulin, SK Klein, P Sonneveld, D Siegel, J Bla..., Leukemia, 1/1/2011
• Initial genome sequencing and analysis of multiple myeloma  
  Chapman M, Lawrence M, Keats J, Cibulskis K, Sougnez C, Schinzel A, Harview C, Brunet J, Ahmann G, Adli M, Anderson K, Ardlie K, Auclair D et al, Nature, 1/1/2011
• Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma  
  Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG, J Clin Oncol, 1/17/2010
• The current status and future of multiple myeloma in the clinic  
  Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J, Clin Lymphoma Myeloma, 1/1/2010
• Conflicts of interest, authorship, and disclosures in industry-related scientific publications  
  Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK et al, Mayo Clin Proc, 1/1/2010
• Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label random...  
  Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams Me, Abonour R, Siegel DS, Katz M, Greipp PR; for the eastern Cooperative Oncology Group, Lancet Oncol, 1/1/2010
• Inaccuracies in 24-hour Urine Testing for Monoclonal Gammopathies  
  Siegel D, McBride L, Bilotti e, Lendvai N, Gonsky J, Berges T, Schillen D, McNeill A, Schmidt L, van Hoeven K, Lab Medicine, 1/1/2009
• Serum Free Light Chain Analysis for Diagnosis, Monitoring and Prognosis of Monoclonal Gammopathies  
  Siegel D, Bilotti e, van Hoeven K, Lab Medicine, 1/1/2009
• First thalidomide clinical trial in multiple myeloma: a decade later  
  van Rhee F, Shaughnessy Jr JD, Anaissie e, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B, Blood, 1/15/2008
• Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma  
  Richardson P, Mitsiades C, Colson K, Reilly e, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D, Leuk Lymphoma, 1/1/2008
• Multiple Primary Cutaneous Plasmacytomas  
  Fitzhugh VA, Siegel D, Bhattacharyya PK, J Clin Pathol, 1/1/2008
• The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement  
  Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, erdem e, Giralt S, Jagannath S, Kyle RA, Legrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall L, Roodman D, ..., Leukemia, 1/1/2008
• Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America  
  Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer eA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Kni..., N engl J Med, 1/22/2007
• A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings  
  Stadtmauer eA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, S..., Clin Adv Hematol Oncol, 1/1/2007
• Long-term outcome results of the first tandem autotransplant trial for multiple myeloma  
  Barlogie B, Tricot GJ, van Rhee F, Angtuaco e, Walker R, epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta ..., Br J Haematol, 1/1/2006
• efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multi...  
  Berenson JR, Boccia R, Siegel D, Bozdech M, Stadtmauer e, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russel..., Br J Haematol, 1/1/2006
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib  
  Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S,..., J Clin Oncol, 1/1/2006
• Multiple skin lesions in a patient with multiple myeloma CD30-positive cutaneous large cell lymphoproliferative disorder  
  Qian YW, Siegel D, Bhattacharyya P, Arch Pathol Lab Med, 1/1/2006
• Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma  
  Berenson JR, Jagannath S, Barlogie B, Siegel D, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, esseltine..., Cancer, 1/15/2005
• An unusual finding in the renal medulla  
  Tsao L, Siegel DS, Zeveloff S, Bhagat G, D'Agati VD, Markowitz GS, Am J Kidney Dis, 1/1/2005
• Join now to see all

Books/Book Chapters

• Advances in Internal Medicine 
  Chapter: Advances in the treatment of multiple myeloma. 
  Barlogie B, Jagannath S, Tricot G, Desikan KR, Fassas A and Siegel DMosby-Year Book1998
• C-Myc in B-Cell Neoplasia. 14th Workshop on Mechanisms in B-Cell Neoplasia 
  Chapter: Myc/Max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells. 
  Siegel DS, Terry JA, Koury J, Barlogie B, epstein J and Feinman REditors: Potter M and Melchers F.Springer-Verlag1997
• The Interferon System 
  Chapter: Interferon-gamma induction in peripheral blood leukocytes by interleukin-2: Role of monocytes, interleukin-1 and interferon-gamma. 
  Vilcek J, Henriksen-DeStefano D, Siegel D and Le JEditors: Dianziani F and Rossi GB.Raven Press1984

Lectures

• CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all